<DOC>
	<DOCNO>NCT01281605</DOCNO>
	<brief_summary>This study compare effectiveness safety two treatment algorithms insulin detemir initiation titration : active titration algorithm ( perform investigator weekly ) versus usual titration algorithm ( perform study subject weekly ) patient type 2 diabetes poorly control OADs .</brief_summary>
	<brief_title>Comparison Two Titration Programs Adding Insulin Detemir OADs Poorly Controlled Type 2 Diabetes</brief_title>
	<detailed_description>This 24-week , prospective , open-label , randomize , parallel-group study conduct approximately 200 patient type 2 diabetes Taiwan . The effectiveness insulin detemir assess baseline 12 24 week initiation study prescription . The safety follow 24-week study period . Inclusion criterion : Patients must meet following criterion : 1 . Men woman type 2 diabetes . 2 . 20 year age . 3 . Patients receive stable dos OADs least 10 week prior screen visit . 4 . Patients inadequate glycemic control ( HbA1C &gt; =7 % &lt; 11 % ) . 5 . Patients willing able cooperate study give sign informed consent . After enrollment , eligible patient randomize 1:1 ratio one follow titration algorithm : - Active titration algorithm : contact investigator telephone weekly . - Usual titration algorithm : contact investigator routine study visit .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<criteria>Patients must meet following criterion : 1 . Men woman type 2 diabetes . 2 . 20 year age . 3 . Patients receive stable dos OADs least 10 week prior screen visit . 4 . Patients inadequate glycemic control ( HbA1C &gt; =7 % &lt; 11 % ) . 5 . Patients willing able cooperate study give sign informed consent . 1 . Patients type 1 diabetes . 2 . Renal dialysis patient . 3 . History hypoglycemia unawareness . 4 . Patients receive insulin 2 week receive insulin treatment within 4 week prior screen visit . 5 . Patients receive investigational product ( drug device ) within 4 week prior screen visit . 6 . Patients hypersensitive insulin detemir excipients . 7 . Patients currently pregnant/lactating , prepare pregnancy lactation .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Type 2 diabetes</keyword>
	<keyword>Basal insulin</keyword>
	<keyword>Insulin detemir</keyword>
	<keyword>Insulin titration algorithm</keyword>
</DOC>